KaloBios Initiates Phase 2 Expansion Portion of Study of KB004 in Hematologic Malignancies

[PR Newswire] – SOUTH SAN FRANCISCO, Calif., Feb. 11, 2014 /PRNewswire/ — KaloBios Pharmaceuticals, Inc. (KBIO) today announced that the company has begun treating patients in the Phase 2 expansion portion of study KB004-01 evaluating KB004, the company more

View todays social media effects on KBIO

View the latest stocks trending across Twitter. Click to view dashboard

See who KaloBios is hiring next, click here to view